These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

896 related items for PubMed ID: 27536906

  • 1. Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer.
    Abikhzer G, Srour S, Fried G, Drumea K, Kozlener E, Frenkel A, Israel O, Fogelman I, Kagna O.
    Nucl Med Commun; 2016 Nov; 37(11):1160-8. PubMed ID: 27536906
    [Abstract] [Full Text] [Related]

  • 2. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
    Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I.
    J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
    [Abstract] [Full Text] [Related]

  • 3. A Prospective Study Comparing 99mTc-Hydroxyethylene-Diphosphonate Planar Bone Scintigraphy and Whole-Body SPECT/CT with 18F-Fluoride PET/CT and 18F-Fluoride PET/MRI for Diagnosing Bone Metastases.
    Löfgren J, Mortensen J, Rasmussen SH, Madsen C, Loft A, Hansen AE, Oturai P, Jensen KE, Mørk ML, Reichkendler M, Højgaard L, Fischer BM.
    J Nucl Med; 2017 Nov; 58(11):1778-1785. PubMed ID: 28798033
    [Abstract] [Full Text] [Related]

  • 4. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
    Caglar M, Kupik O, Karabulut E, Høilund-Carlsen PF.
    Rev Esp Med Nucl Imagen Mol; 2016 Nov; 35(1):3-11. PubMed ID: 26514321
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL, Xue YL, Song HJ, Luo QY.
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [Abstract] [Full Text] [Related]

  • 6. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
    Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, Kemppainen J, Kauppila E, Auren J, Merisaari H, Saunavaara J, Noponen T, Minn H, Aronen HJ, Seppänen M.
    Acta Oncol; 2016 Dec; 55(1):59-67. PubMed ID: 25833330
    [Abstract] [Full Text] [Related]

  • 7. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T, Obara P, Taviani V, Gambhir SS, Vasanawala S, Iagaru A.
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [Abstract] [Full Text] [Related]

  • 8. Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma.
    Chakraborty D, Bhattacharya A, Mete UK, Mittal BR.
    Clin Nucl Med; 2013 Aug; 38(8):616-21. PubMed ID: 23603596
    [Abstract] [Full Text] [Related]

  • 9. Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial.
    Bénard F, Harsini S, Wilson D, Zukotynski K, Abikhzer G, Turcotte E, Cossette M, Metser U, Romsa J, Martin M, Mar C, Saad F, Soucy JP, Eigl BJ, Black P, Krauze A, Burrell S, Nichol A, Tardif JC.
    Lancet Oncol; 2022 Dec; 23(12):1499-1507. PubMed ID: 36343655
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.
    Gerety EL, Lawrence EM, Wason J, Yan H, Hilborne S, Buscombe J, Cheow HK, Shaw AS, Bird N, Fife K, Heard S, Lomas DJ, Matakidou A, Soloviev D, Eisen T, Gallagher FA.
    Ann Oncol; 2015 Oct; 26(10):2113-8. PubMed ID: 26202597
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases.
    Iagaru A, Mittra E, Dick DW, Gambhir SS.
    Mol Imaging Biol; 2012 Apr; 14(2):252-9. PubMed ID: 21479710
    [Abstract] [Full Text] [Related]

  • 18. 18F-Fluoride PET/CT and 99mTc-MDP SPECT/CT can detect bone cancer at early stage in rodents.
    Alves CRR, Faria DP, Carneiro CG, Garcez AT, Gutierrez VP, das Neves W, de Almeida NR, Cury Y, Chammas R, Brum PC.
    Life Sci; 2018 Aug 01; 206():29-34. PubMed ID: 29778807
    [Abstract] [Full Text] [Related]

  • 19. 18F-NaF-PET/CT and 99mTc-MDP Bone Scintigraphy in the Detection of Bone Metastases in Prostate Cancer.
    Langsteger W, Rezaee A, Pirich C, Beheshti M.
    Semin Nucl Med; 2016 Nov 01; 46(6):491-501. PubMed ID: 27825429
    [Abstract] [Full Text] [Related]

  • 20. Diagnostic bone imaging in patients with prostate cancer: patient experience and acceptance of NaF-PET/CT, choline-PET/CT, whole-body MRI, and bone SPECT/CT.
    Dyrberg E, Larsen EL, Hendel HW, Thomsen HS.
    Acta Radiol; 2018 Sep 01; 59(9):1119-1125. PubMed ID: 29313360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.